FDA panel recommends Glaxo’s Votrient for sarcoma

WASHINGTON (Reuters) – A Food and Drug Administration panel on Tuesday recommended GlaxoSmithKline Plc’s Votrient for treatment of advanced soft-tissue sarcoma, a relatively rare but aggressive form of cancer. The FDA advisory committee of outside experts voted 11-2 to find that the drug’s ability to improve short-term survival without worsening symptoms in patients who receive chemotherapy outweighed adverse risks and a lack of evidence that it can extend overall survival. (Reporting by David Morgan; Editing by Lisa Von Ahn)